• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Review on quality of life in CRPC patients].

作者信息

Miller Kurt

机构信息

Klinik für Urologie, Urologische Klinik, Charité-Universitätsmedizin Berlin.

出版信息

Aktuelle Urol. 2017 May;48(3):219-224. doi: 10.1055/s-0043-100492. Epub 2017 Jun 14.

DOI:10.1055/s-0043-100492
PMID:28614882
Abstract

Health-related quality of life (HRQoL) deteriorates rapidly in patients with advanced-stage cancer, with patients seriously disturbed by fatigue, sleep disorders, bone pain, constipation and other disease related symptoms. As treatment and prognosis continues to improve, reducing symptoms and improving quality of life with minimum of toxicities have become important therapeutic goals. The effectiveness of abiraterone acetate and enzalutamide in both prolonging life and improving quality of life in asymptomatic or mildly symptomatic patients with metastatic castrations-resistant prostate cancer (mCRPC) has been clinically proven.

摘要

相似文献

1
[Review on quality of life in CRPC patients].
Aktuelle Urol. 2017 May;48(3):219-224. doi: 10.1055/s-0043-100492. Epub 2017 Jun 14.
2
AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.循环肿瘤细胞簇中的AR-V7作为去势抵抗性前列腺癌患者醋酸阿比特龙和恩杂鲁胺治疗的预测生物标志物。
Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.
3
[Monitoring of treatment for metastatic castration-resistant prostate cancer].[转移性去势抵抗性前列腺癌治疗的监测]
Aktuelle Urol. 2017 May;48(3):225-229. doi: 10.1055/s-0042-117570. Epub 2017 Jun 14.
4
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.恩杂鲁胺联合醋酸阿比特龙治疗骨转移去势抵抗性前列腺癌患者。
Eur Urol Oncol. 2020 Feb;3(1):119-127. doi: 10.1016/j.euo.2019.01.008. Epub 2019 Apr 20.
5
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.恩扎卢胺对去势抵抗性前列腺癌男性患者首次骨骼相关事件、疼痛和生活质量的影响：来自随机、III 期 AFFIRM 试验的结果。
Lancet Oncol. 2014 Sep;15(10):1147-56. doi: 10.1016/S1470-2045(14)70303-1. Epub 2014 Aug 4.
6
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.阿比特龙治疗后化疗初治转移性去势抵抗性前列腺癌患者应用恩扎卢胺的疗效。
Eur Urol. 2015 Jan;67(1):23-29. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.
7
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.恩杂鲁胺作为转移性去势抵抗性前列腺癌的四线或五线治疗选择
Oncology. 2016;91(5):267-273. doi: 10.1159/000448219. Epub 2016 Aug 20.
8
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.恩扎卢胺和阿比特龙对去势抵抗性前列腺癌患者骨骼相关事件和骨影像学无进展生存期的影响：随机对照试验的间接比较。
Crit Rev Oncol Hematol. 2017 Dec;120:227-233. doi: 10.1016/j.critrevonc.2017.09.008. Epub 2017 Oct 16.
9
Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.醋酸阿比特龙与恩杂鲁胺：治疗多西他赛后转移性去势抵抗性前列腺癌的疗效相似：单中心经验
Anticancer Res. 2019 Jul;39(7):3901-3908. doi: 10.21873/anticanres.13541.
10
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.醋酸阿比特龙治疗初治转移性去势抵抗性前列腺癌患者时骨靶向治疗的影响：研究COU-AA-302的事后分析
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.

引用本文的文献

1
Identification of pyrimidine metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical treatment in prostate cancer.基于嘧啶代谢的前列腺癌分子亚型鉴定及预后特征预测免疫格局并指导临床治疗
Ann Med. 2025 Dec;57(1):2449584. doi: 10.1080/07853890.2025.2449584. Epub 2025 Jan 13.